Our look is new. Our purpose is the same. Learn more about our brand evolution.
Reposted from Facio Therapies, Leiden, The Netherlands – August 30, 2018 Facio Therapies announced today that it has selected a second series of potential candidates for FSHD drug development. This […]
A review of published studies to improve our understanding by Amanda Hill, Highlands Ranch, Colorado As many as 20 percent of patients with FSHD have an “infantile” or “early-onset” form, which […]
The field has made astonishingly fast progress by Charis Himeda, PhD, University of Nevada, Reno Nearly 150 researchers, clinicians, patients, and industry partners convened at the FSH Society’s 2018 International Research […]
When the FSH Society made its initial grant award in 2016 to help establish the nationwide FSHD Clinical Trial Research Network (CTRN), we expected the network would be able to […]
Here’s the recording of our FSH Society webinar on August 1, 2018. Dr. Leung is a neurologist at Kennedy Krieger Institute Center for Genetic Muscle Disorders and an assistant professor in […]
